CPO
VNDA icon

Cerity Partners OCIO’s Vanda Pharmaceuticals VNDA Stock Holding History

Cerity Partners OCIO’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-29,039
Closed -$281K – 377
2020
Q3 		$281K Buy
+29,039
New +$310K 0.01% 298

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cerity Partners OCIO's VNDA Position: Q4 2020 in Review

Cerity Partners OCIO sold out of Vanda Pharmaceuticals (VNDA) in Q4 2020, closing a stake of 29,039 shares — an estimated $281K sold.

Cerity Partners OCIO first reported a position in VNDA in Q3 2020 and held it in 1 quarter. The position peaked at $281K in Q3 2020. 178 funds tracked by Wall St. Rank hold VNDA as of Q4 2020.

  • Cerity Partners OCIO reported no remaining Vanda Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Cerity Partners OCIO sold 29,039 Vanda Pharmaceuticals shares in Q4 2020, an estimated $281K.
  • Cerity Partners OCIO first reported a position in Vanda Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Cerity Partners OCIO's Vanda Pharmaceuticals position peaked at $281K in Q3 2020.
  • 178 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2020.

Based on Cerity Partners OCIO's 13F filing for Q4 2020, filed 10 Feb 2021.